Opus Genetics, Inc.IRDEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | 8.16% | 2.6M | — | 2024-10-29 |
Insider Transactions
Net 90d: −$180.7K · buys $0 / sells $180.7KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-20 | Sean Ainsworth | Director | Grant | 24.4K | $0.00 | $0 |
| 2026-04-20 | Jean Bennett | Director | Grant | 24.4K | $0.00 | $0 |
| 2026-04-20 | Susan Benton | Director | Grant | 24.4K | $0.00 | $0 |
| 2026-04-20 | MANUSO JAMES S J | Director | Grant | 24.4K | $0.00 | $0 |
| 2026-04-20 | Rodgers Richard J | Director | Grant | 24.4K | $0.00 | $0 |
| 2026-04-20 | Cam Gallagher | Director | Grant | 24.4K | $0.00 | $0 |
| 2026-04-20 | Graves Adrienne L | Director | Grant | 24.4K | $0.00 | $0 |
| 2026-03-16 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Sell (open market) | 2.8K | $5.25 | $14.8K |
| 2026-03-16 | SCHACHLE JOSEPH K | Chief Operating Officer | Sell (open market) | 3.7K | $5.25 | $19.5K |
| 2026-03-16 | Ashwath Jayagopal | Chief Scientific & Dev. Ofc. | Sell (open market) | 3.7K | $5.12 | $19.0K |
1–10 of 11
Page 1 / 2